Patents Represented by Attorney, Agent or Law Firm John W. Wallen, III
-
Patent number: 7858344Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: March 15, 2010Date of Patent: December 28, 2010Assignee: Ambrx, Inc.Inventors: Andrew Paulsel, Ho Sung Cho
-
Patent number: 7846689Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: March 15, 2010Date of Patent: December 7, 2010Assignee: Ambrx, Inc.Inventors: Andrew Paulsel, Ho Sung Cho
-
Patent number: 7838265Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: March 15, 2010Date of Patent: November 23, 2010Assignee: Ambrx, Inc.Inventors: Andrew Paulsel, Ho Sung Cho
-
Patent number: 7829310Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: March 15, 2010Date of Patent: November 9, 2010Assignee: Ambrx, Inc.Inventors: Andrew Paulsel, Ho Sung Cho
-
Patent number: 7820766Abstract: The invention provides water-soluble compounds that include a polymer and at least one terminal azide or acetylene moiety. Also provided are highly efficient methods for the selective modification of proteins with PEG derivatives, which involves the selective incorporation of non-genetically encoded amino acids, e.g., those amino acids containing an azide or acetylene moiety, into proteins in response to a selector codon and the subsequent modification of those amino acids with a suitably reactive PEG derivative.Type: GrantFiled: May 6, 2010Date of Patent: October 26, 2010Assignee: Ambrx, Inc.Inventor: Troy E. Wilson
-
Patent number: 7816320Abstract: Formulations of modified human growth hormone polypeptides are provided.Type: GrantFiled: December 21, 2005Date of Patent: October 19, 2010Assignee: AMBRX, Inc.Inventors: Anna-Maria Hays, Ying Buechler, David C. Litzinger
-
Patent number: 7737226Abstract: The invention provides water-soluble compounds that include a polymer and at least one terminal azide or acetylene moiety. Also provided are highly efficient methods for the selective modification of proteins with PEG derivatives, which involves the selective incorporation of non-genetically encoded amino acids, e.g., those amino acids containing an azide or acetylene moiety, into proteins in response to a selector codon and the subsequent modification of those amino acids with a suitably reactive PEG derivative.Type: GrantFiled: January 24, 2007Date of Patent: June 15, 2010Assignee: AMBRX, Inc.Inventor: Troy E. Wilson
-
Patent number: 7736872Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: December 1, 2005Date of Patent: June 15, 2010Assignee: Ambrx, Inc.Inventors: Andrew Paulsel, Ho Sung Cho
-
Patent number: 7638299Abstract: Modified biosynthetic polypeptide molecules, methods for manufacturing, and uses thereof are provided.Type: GrantFiled: July 21, 2005Date of Patent: December 29, 2009Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Anna-Maria Hays, Troy E. Wilson, David C. Litzinger, Roberto Mariani, Bruce E. Kimmel, William M. Keefe
-
Patent number: 7632924Abstract: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.Type: GrantFiled: June 17, 2005Date of Patent: December 15, 2009Assignee: Ambrx, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Troy E. Wilson, Thomas P. Cujec, Feng Tian, Anna-Maria Hays, Bruce E. Kimmel, Lillian Ho
-
Patent number: 7632823Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNA's, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNA's/synthetases are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins using these orthogonal pairs.Type: GrantFiled: December 1, 2005Date of Patent: December 15, 2009Assignee: Ambrx, Inc.Inventor: Feng Tian
-
Patent number: 7230068Abstract: The invention provides water-soluble compounds that include a polymer and at least one terminal azide or acetylene moiety. Also provided are highly efficient methods for the selective modification of proteins with PEG derivatives, which involves the selective incorporation of non-genetically encoded amino acids, e.g., those amino acids containing an azide or acetylene moiety, into proteins in response to a selector codon and the subsequent modification of those amino acids with a suitably reactive PEG derivative.Type: GrantFiled: October 7, 2004Date of Patent: June 12, 2007Assignee: Ambrx, Inc.Inventor: Troy E. Wilson
-
Patent number: 6673792Abstract: Broad-spectrum anti-emetic pharmaceutical compositions are disclosed. The discloses broad-spectrum ant-emetics disclosed herein comprise selected neuroreceptor antagonists specifically formulated to treat and prevent to most common forms of emesis. In one embodiment the ant-emetic compositions include lorazepam, diphenhydramine, promethazine, and metoclopramide. The pharmaceutical compositions include, but are not limited to oral and parenteral forms and may include one or more pharmaceutically acceptable excipient.Type: GrantFiled: July 11, 2002Date of Patent: January 6, 2004Assignee: Upchuck, LLCInventor: James Peter Summerville
-
Patent number: 6629454Abstract: A low tire pressure monitoring device that is affixed to a tire valve stem and methods of using the same. The monitoring device comprises a housing having a counter-pressure chamber, a main pressure chamber, and a flexible membrane that separates the two chambers. The monitoring device is calibrated by trapping the tire's initial air pressure in the counter-pressure chamber. The air pressure within the main pressure chamber is equivalent to the air pressure within the tire. Over the course of time, the air pressure within the tire and concomitantly the air pressure within the main pressure chamber decreases. When the pressure in the counter-pressure is greater than the pressure within the main pressure chamber, the flexible membrane touches and completes an electrical circuit and a warning signal is emitted.Type: GrantFiled: November 21, 2001Date of Patent: October 7, 2003Inventor: Torbjörn Boson Lundqvist
-
Patent number: 6548270Abstract: DNA encoding human acid sensing ion channel BnaC4 has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: March 3, 2000Date of Patent: April 15, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Adrienne Elizabeth Dubin, Jayashree Pyati, Rene Huvar, Mark G. Erlander
-
Patent number: 6485957Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process.Type: GrantFiled: August 31, 1999Date of Patent: November 26, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
-
Patent number: 6458552Abstract: The present invention describes peptide substrates of the metalloproteases, ADAM8, ADAM15 and MDC-L. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases. The invention further describes CD23 processing activity for these enzymes that may have important therapeutic implications for the use of inhibitors of these enzymes in allergic diseases such as asthma.Type: GrantFiled: June 6, 2000Date of Patent: October 1, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Anne Fourie, Lars Karlsson, Robin Thurmond
-
Patent number: 6458564Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease T. The deduced amino acid sequence encodes a prepro form of 290 amino acids, and its alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease T mRNA is expressed in stomach, testis, retina, fibroblasts, spinal cord, and several regions of the brain. Protease T MRNA is also found in leukocytes and in the Jurkat (ATCC TIB-152) T cell line. Thus, this protease is potentially involved in gastric, testicular, retinal, dematological, neurological/neurodegenerative and/or immunological disorders. The protease T gene maps to human chromosome 16p13.3 which is near the tryptase locus. Enzymatically active protease T, we have generated, is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators.Type: GrantFiled: August 31, 1999Date of Patent: October 1, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Grodon
-
Patent number: 6455278Abstract: DNA encoding human VR1 receptor has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: February 8, 2000Date of Patent: September 24, 2002Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Adrienne Elizabeth Dubin, Arne Huvar, Charles A. Glass, Mark G. Erlander
-
Patent number: 6437100Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: August 21, 2000Date of Patent: August 20, 2002Assignee: Ortho Pharmaceutical CorporationInventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati